Hyperparathyroidism

Thrice-Weekly Calcimimetic Dosing Feasible for Patients on Hemodialysis With Hyperparathyroidism

Thrice-Weekly Calcimimetic Dosing Feasible for Patients on Hemodialysis With Hyperparathyroidism

By

In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels.

Etelcalcetide Found to Increase BMD in Secondary Hyperparathyroidism

Etelcalcetide Found to Increase BMD in Secondary Hyperparathyroidism

By

Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.

Outcomes of Primary Hyperparathyroidism Treatments During Pregnancy

Outcomes of Primary Hyperparathyroidism Treatments During Pregnancy

By

The rate of pre-eclampsia and preterm delivery was higher in medically managed patients with hyperparathyroidism.

Effects of Vitamin D3 Treatment on Bone Strength in Postmenopausal Women

Effects of Vitamin D3 Treatment on Bone Strength in Postmenopausal Women

By

Investigators sought to determine the effects of vitamin D3 supplementation in postmenopausal women with low serum 25(OH)D and high parathyroid hormone levels.

Prevalence and Predictors of Renal Calcification in Primary Hyperparathyroidism

Prevalence and Predictors of Renal Calcification in Primary Hyperparathyroidism

By

Investigators aimed to assess biochemical predictors of renal calcifications in patients with primary hyperparathyroidism.

Parathyroidectomy for Secondary, Tertiary Hyperparathyroidism Increases Morbidity and Mortality

Parathyroidectomy for Secondary, Tertiary Hyperparathyroidism Increases Morbidity and Mortality

By

After parathyroidectomy, morbidity and mortality rates were considerably higher in patients with secondary and tertiary vs primary hyperparathyroidism.

Increased Primary Hyperparathyoridism Risk Linked to Weight in Women

Increased Primary Hyperparathyoridism Risk Linked to Weight in Women

Data were collected from the Nurses' Health Study I to examine the relationship between BMI and primary hyperparathyroidism risk.

FDA Approves Etelcalcetide for Secondary Hyperparathyroidism in Chronic Kidney Disease

FDA Approves Etelcalcetide for Secondary Hyperparathyroidism in Chronic Kidney Disease

By

The drug's approval was based on 2 successful phase 3 trials.

Etelcalcetide Examined in Hemodialysis Patients With Secondary Hyperparathyroidism

Etelcalcetide Examined in Hemodialysis Patients With Secondary Hyperparathyroidism

By

Etelcalcetide shows promise for reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.

Risk for Secondary Hyperparathyroidism Up With Furosemide Use

Risk for Secondary Hyperparathyroidism Up With Furosemide Use

By

Study reveals 6-fold higher risk of secondary hyperparathyroidism in patients on furosemide vs hydrochlorothiazide.

Parathyroidectomy Improves Quality of Life in Primary Hyperparathyroidism

Parathyroidectomy Improves Quality of Life in Primary Hyperparathyroidism

Quality-of-life scores improved significantly after successful parathyroidectomy.

Parathyroidectomy May Reduce Fracture Risk in Primary Hyperparathyroidism

Parathyroidectomy May Reduce Fracture Risk in Primary Hyperparathyroidism

Reduced fracture risk for surgery; bisphosphonate treatment no better than observation

Parathyroidectomy Bested Cinacalcet for Hyperparathyroidism After Kidney Transplant

Parathyroidectomy Bested Cinacalcet for Hyperparathyroidism After Kidney Transplant

By

Recent data showed that parathyroidectomy is more effective for controlling hypercalcemia after kidney transplants in patients with persistent hyperparathyroidism.

Chronic Proton Pump Inhibitor Exposure Tied to Hyperparathyroidism in Elderly

Chronic Proton Pump Inhibitor Exposure Tied to Hyperparathyroidism in Elderly

The correlation persists regardless of concurrent oral bisphosphonate administration.

Primary Hyperparathyroidism Screening Needs Improvement

Primary Hyperparathyroidism Screening Needs Improvement

By

More patients with abnormal bone mineral density should undergo screening for primary hyperparathyroidism.

AMG 416 Succeeds in Secondary Hyperparathyroidism Trial

AMG 416 Succeeds in Secondary Hyperparathyroidism Trial

AMG 416 demonstrated positive results for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Sign Up for Free e-Newsletters



CME Focus